Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analys...

by Selma Atalay, Juul M.P.A. van den Reek, Marisol E. Otero, Marcellus D. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. Koetsier, Maartje M. Berends, Peter C.M. van de Kerkhof, Hans M.M. Groenewoud, Alfons A. den Broeder, Elke M.G.J. de Jong, Wietske Kievit
Published 2020-12-01